Treatment preferences for active surveillance versus active treatment among men with low-risk prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 8, 2016, Pages 1240-1250

  Taylor, Kathryn L ^a   Hoffman, Richard M ^b   Davis, Kimberly M ^a   Luta, George ^a   Leimpeter, Amethyst ^c   Lobo, Tania ^a   Kelly, Scott P ^a   Shan, Jun ^c   Aaronson, David ^d   Tomko, Catherine A ^a   Starosta, Amy J ^a   Hagerman, Charlotte J ^a   Van Den Eeden, Stephen K ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c DIVISION OF RESEARCH   (United States)

^d Department of Urology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SURVEILLANCE; ACTIVE TREATMENT; ADULT; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; EPIDEMIOLOGICAL MONITORING; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; LONGITUDINAL STUDY; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; WATCHFUL WAITING; AGED; ANXIETY; DECISION MAKING; MIDDLE AGED; PROSTATE TUMOR; PSYCHOLOGY; QUESTIONNAIRE; RISK; STATISTICAL MODEL;

AGED; ANXIETY; DECISION MAKING; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT PREFERENCE; PROSTATIC NEOPLASMS; RISK; SURVEYS AND QUESTIONNAIRES; WATCHFUL WAITING;

EID: 84982958579     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-1079     Document Type: Article

References (61)

1. American Cancer Society [Internet]. Cancer facts and figures 2016. Atlanta: American Cancer Society; 2016 [cited 2016 Apr 10]. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf.
2. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
3. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104:1335-42.
4. Etzioni R, Penson DF, Legler JM, di TD, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
5. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
6. Yao SL, Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst 2002;94:958-60.
7. Chamie K, Williams SB, Hu JC. Population-based assessment of determining treatments for prostate cancer. JAMA Oncol 2015;1:60-7.
8. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28: 1117-23.
9. Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer. J Urol 2014;192:75-81.
10. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, et al. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med 2014;174:1450-9.
11. Jacobs BL, Zhang Y, Schroeck FR, Skolarus TA, Wei JT, Montie JE, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA 2013;309:2587-95.
12. Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010;170:440-50.
13. Mishra MV, Shen X, Den RB, Champ CE, Trabulsi EJ, Lallas CD, et al. Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. Am J Clin Oncol 2013;36:606-11.
14. Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med 2010;170:1256-61.
15. Shappley WVIII, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009;27: 4980-5.
16. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol 2010;183:2206-12.
17. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Long-term outcomes among localized prostate cancer survivors: healthrelated quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005;23:2772-80.
18. Mols F, Korfage IJ, Vingerhoets AJ, Kil PJ, Coebergh JW, Essink-Bot ML, et al. Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. Int J Radiat Oncol Biol Phys 2009;73: 30-8.
19. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.
20. Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Longterm disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 2012;30:2768-75.
21. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in themanagement ofmen with localized prostate cancer. Ann Intern Med 2012;156:591-5.
22. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976-83.
23. Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2013;189:S19-S25.
24. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
25. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Longterm follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272-7.
26. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015;33: 3379-85.
27. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes ofmen with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
28. Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014;15:1109-18.
29. American Urological Association [Internet]. Guideline for the management of clinically localized prostate cancer: 2007. Linthicum (MD): American Urological Association Education and Research, Inc.; 2007[cited 2015 Sep 28]. Available from: http://www.auanet.org/education/guidelines/prostate-cancer.cfm.
30. National Comprehensive Cancer Network [Internet]. NCCN clinical practice guidelines in oncology: prostate cancer. Version 2.2014. Fort Washington (PA): NCCN; 2014[cited 2015 Sep 28]. Available from: http://www.trikobe.org/nccn/guideline/urological/english/prostate.pdf.
31. National Institutes of Health [Internet]. NIH state-of-the-science conference: role of active surveillance in the management of men with localized prostate cancer. December 5-7, 2011, Bethesda, Maryland. Bethesda (MD): NIH; 2011[cited 2015 Sep 28]. Available from: http://consensus. nih.gov/2011/prostatefinalstatement.htm.
32. Carter HB. Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr 2012;2012: 175-83.
33. Chapple A, Ziebland S, Herxheimer A, McPherson A, Shepperd S, Miller R. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int 2002;90:257-64.
34. Davison BJ, Breckon E. Factors influencing treatment decisionmaking and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns 2012;87:369-74.
35. van den Bergh RC, Korfage IJ, Bangma CH. Psychological aspects of active surveillance. Curr Opin Urol 2012;22:237-42.
36. Xu J, Neale AV, Dailey RK, Eggly S, Schwartz KL. Patient perspective on watchful waiting/active surveillance for localized prostate cancer. J Am Board Fam Med 2012;25:763-70.
37. Ritchie A, Marbury D, Verdon DR, Mazzolini C, Boyles S. Shifting reimbursement models: the risks and rewards for primary care. Medical Economics [Internet]. 2014 Apr 8[cited 2015 Sep 28]; [about 13 p.]. Available from: http://medicaleconomics.modernmedicine.com/medical-economics/content/tags/aca/shifting-reimbursement-models-risks-and-rewardsprimary-care?page=full.
38. U.S. Department of Health and Human Services [Internet]. HHS.gov. Health Care. Washington: U.S. Department of Health and Human Services; [cited 2016 Apr 10]. Available from: http://www.hhs.gov/healthcare/.
39. U.S. Census Bureau [Internet]. Statistical abstract of the United States: 2012. Health and Nutrition. Washington: U.S. Census Bureau; 2012[cited 2015 Sep 28]. Available from: https://www.census.gov/library/publications/2011/compendia/statab/131ed/health-nutrition.html.
40. Zafar SY, Alexander SC, Weinfurt KP, Schulman KA, Abernethy AP. Decisionmaking and quality of life in the treatment of cancer: a review. Support Care Cancer 2009;17:117-27.
41. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
42. Legare F, Kearing S, Clay K, Gagnon S, D'Amours D, Rousseau M, et al. Are you SURE?: Assessing patient decisional conflict with a 4-item screening test. Can Fam Physician 2010;56:e308-14.
43. O'Connor AM. User Manual - Decisional Conflict Scale. [Internet]. Ottawa: Ottawa Hospital Research Institute; 1993[updated 2010; cited 2015 Sep 28]. 16 p. Available from: http://decisionaid.ohri.ca/docs/develop/User-Manuals/UM-Decisional-Conflict.pdf.
44. Clark JA, Inui TS, Silliman RA, Bokhour BG, Krasnow SH, Robinson RA, et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21:3777-84.
45. Degner L. Patient participation in treatment decision making. Axone 1992;14:13-4.
46. Taylor KL, Davis JLIII, Turner RO, Johnson L, Schwartz MD, Kerner JF, et al. Educating African American men about the prostate cancer screening dilemma: a randomized intervention. Cancer Epidemiol Biomarkers Prev 2006;15:2179-88.
47. Taylor KL, Williams RM, Davis K, Luta G, Penek S, Barry S, et al. Decision making in prostate cancer screening using decision aids vs usual care: a randomized clinical trial. JAMA Intern Med 2013;173:1704-12.
48. Williams RM, Davis KM, Luta G, Edmond SN, Dorfman CS, Schwartz MD, et al. Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer. Patient Educ Couns 2013;91:329-36.
49. Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Making 2001;21:37-44.
50. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 2015;314:80-2.
51. Ritch CR, Graves AJ, Keegan KA, Ni S, Bassett JC, Chang SS, et al. Increasing use of observation among men at low risk for prostate cancer mortality. J Urol 2015;193:801-6.
52. Weiner AB, Patel SG, Etzioni R, Eggener SE. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 2015;193:95-102.
53. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC. Contemporary use of initial active surveillance among men in Michigan with lowrisk prostate cancer. Eur Urol 2015;67:44-50.
54. Xu J, Dailey RK, Eggly S, Neale AV, Schwartz KL. Men's perspectives on selecting their prostate cancer treatment. J Natl Med Assoc 2011;103:468-78.
55. Fowler FJ Jr., McNaughton CM, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000;283:3217-22.
56. Underwood WIII, Orom H, Poch M, West BT, Lantz PM, Chang SS, et al. Multiple physician recommendations for prostate cancer treatment: a Pandora's box for patients? Can J Urol 2010;17:5346-54.
57. Davison BJ, Oliffe JL, Pickles T, Mroz L. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum 2009;36:89-96.
58. Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int 2011;108: 1787-93.
59. Henrikson NB, Ellis WJ, Berry DL. "It's not like I can change my mind later": reversibility and decision timing in prostate cancer treatment decisionmaking. Patient Educ Couns 2009;77:302-7.
60. Silk KJ, Perrault EK, Nazione S, Pace K, Hager P, Springer S. Localized prostate cancer treatment decision-making information online: improving its effectiveness and dissemination for nonprofit and government-supported organizations. J Cancer Educ 2013;28:709-16.
61. Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin 2015;65: 239-51.